Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer

Elena Niccolai*, Antonio Taddei†, Federica Ricci*, Simona Rolla†‡, Mario Milco D’Elios*∥, Marisa Benagiano*, Paolo Bechi¶**, Lapo Bencini††, Maria Novella Ringuess‡‡*, Alessandro Pini*, Francesca Castiglione*, Daniele Giordano†‡, Maria Antonietta Satolli†‡, Andrea Coratti†‡, Fabio Cianchi¶**, Daniele Bani*, Domenico Prisco*∥, Francesco Novelli†‡‡* and Amedeo Amedei*∥

*Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, 50134 Florence, Italy
†Immunogenetics and Transplant Biology Service, Azienda Ospedaliera Città della Salute e della Scienza di Torino, via Santena 19, 10126 Turin, Italy
‡Centre for Experimental Research and Medical Studies (CERMS), Azienda Ospedaliera Città della Salute e della Scienza di Torino, via Cherasco 15, 10126 Turin, Italy
§Molecular Biology Center and Department of Molecular Biotechnology and Health Sciences, University of Turin, via Nizza 52, 10126 Turin, Italy
∥Department of Neuro-Skeletal Muscle and Sensory Organs, Interdisciplinary Internal Medicine Unit, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
¶Department of Surgery and Translational Medicine, University of Florence, Viale Michelangiolo 41, 50125 Florence, Italy
**Department of Biomedicine, Azienda Ospedaliera Universitaria Careggi (AOU), Largo Brambilla 3, 50134 Florence, Italy
††Department of Oncology, Division of General and Oncologic Surgery, Azienda Ospedaliero Universitaria Careggi (AOU), Largo Brambilla 3, 50134 Florence, Italy
‡‡Centro Oncologico Ematologico Subalpino (COES), AOU Città della Salute e della Scienza di Torino, 10126 Turin, Italy

Abstract
PDAC (pancreatic ductal adenocarcinoma) is the fifth leading cause of cancer-related death. The causes of this cancer remain unknown, but increasing evidence indicates a key role of the host immune response and cytokines in human carcinogenesis. Intra-tumoral IL (interleukin)-22 levels have been shown to be elevated in PDAC patients. However, little is known regarding the expression and clinical relevance of Th22 cells in human PDAC and, furthermore, which TILs (tumour-infiltrating lymphocytes) are the main producers of IL-22 is unknown. In the present study, we characterized the functional properties of the different subsets of IL-22-producing TILs and analysed their relationship with the TNM staging system and patient survival. We have demonstrated for the first time that, in PDAC patients, the T-cells co-producing IFN-γ (interferon γ) and exerting perforin-mediated cytotoxicity are the major intra-tumoral source of IL-22. In addition, isolated Th22 cells were able to induce apoptosis, which was antagonized by IL-22. Finally, we observed that the IL-22-producing T-cells were significantly increased in tumour tissue and that this increase was positively correlated with TNM staging of PDAC and poorer patient survival. These novel findings support the dual role of the anti-tumour immune system and that IL-22-producing cells may participate in PDAC pathogenesis. Therefore monitoring Th22 levels could be a good diagnostic parameter, and blocking IL-22 signalling may represent a viable method for anti-PDAC therapies.

Key words: IFN-γ, IL-22, pancreatic cancer, Th22, tumour-infiltrating lymphocytes.

INTRODUCTION
Pancreatic cancer is the fifth leading cause of cancer-related death in the developed world, with more than 260000 annual deaths worldwide [1] and with a dismal 5-year survival (5%). The lethality of pancreatic cancer is due to its aggressive nature and its tendency to remain asymptomatic until the tumour reaches an advanced stage, limiting the likelihood of early diagnosis. At the time of initial presentation, most pancreatic cancers are locally advanced or metastatic and need multimodal therapy [2], hence the need to find factors that may facilitate earlier diagnosis and improve prognosis of this neoplasia.

Pancreatic cancer originates in the ductal epithelium and evolves from a pre-malignant lesion to fully invasive cancer. The causes of pancreatic cancer remain unknown, although some studies have shown that chronic inflammation is a common

Abbreviations: BFA, brefeldin A; FoxP3, forkhead box P3; IFN-γ, interferon γ; IL, interleukin; IL-10R2, IL-10 receptor 2; IL-22R, IL-22 receptor; mAb, monoclonal antibody; PBMC, peripheral blood mononuclear cell; PD-1, programmed cell death 1; PDAC, pancreatic ductal adenocarcinoma; Tcc, T-cell clone(s); Th, T helper; TIL, tumour-infiltrating lymphocyte.

Correspondence: Professor Amedeo Amedei (email aamedei@unifi.it) or Professor Francesco Novelli (email franco.novelli@unifi.it).
feature of actively growing pancreatic tumours [3]. Moreover, increasing evidence has shown that the host immune response and related inflammatory and immune mediators, such as cytokines, participate in human carcinogenesis [4,5]. IL (interleukin)-22, which belongs to the IL-10 cytokine family, is a T-cell-derived cytokine that mediates epithelial immunity and mucosal tissue repair [6]. IL-22 triggers intracellular signalling by binding to a heterodimeric receptor complex that is composed of IL-22R1 (IL-22 receptor 1) and IL-10R2 (IL-10 receptor 2) [7]. However, the cellular responsiveness of IL-22 is mainly determined by IL-22R1, which is selectively expressed on non-immune cells [8], such as hepatocytes [9], keratinocytes [10], colonic epithelial cells [11] and, particularly, pancreatic cells [12,13].

Principal sources of IL-22 include CD4+ Th (T helper) cells, CD8+ CTLs (cytotoxic T-cells), γδ T-cells and ILCs (innate lymphoid cells), encompassing NK (natural killer) cells, LTI (lymphoid tissue inducer)-like cells [14,15] and NKT (natural killer T) cells [16]. Although several IL-22-producing CD4+ T-cells also produce other cytokines, such as IL-17 or IFN-γ (interferon γ) [17], some, only secrete IL-22 [18]. These CD4+ T-cells that exclusively secrete IL-22 are known as Th22 cells and have been recently identified as the main producers of IL-22 in the peripheral blood [19,20]. Th22 cells play important roles in many inflammatory diseases, such as psoriasis [21], rheumatoid arthritis [22] and multiple sclerosis [23]. Moreover, IL-22 plays a pro-tumour role in cancers of the gastrointestinal tract. Gastric tumours show increased infiltration of Th22, which correlates with tumour stage and poor prognosis [24]. In addition, compared with healthy controls, gastric cancer patients also have higher circulating frequencies of IL-17- and IL-22-producing T-cells, which are positively associated with cancer stage and negatively with patient survival [25]. In colorectal cancer, levels of both IL-17 and IL-22 are positively correlated with the tumour stage [26], and serum IL-22 is elevated in chemoresistant patients [27]. Moreover, IL-22 administration to human colorectal cancer cell lines renders them chemoresistant [27]. In pancreatic cancer, intra-tumoral IL-22 levels and frequency of Th22 cells are elevated compared with the peripheral blood of patients and healthy donors [28]. Similarly, expression of both IL-22 and IL-22R1 is elevated in tissue sections of PDAC (pancreatic ductal adenocarcinoma) tissue [29]. However, little is known regarding the expression and clinical relevance of Th22 in pancreatic cancer and, furthermore, which TILs (tumour-infiltrating lymphocytes) are the main producers of IL-22 is unknown. In the present study, we have investigated the role of IL-22-producing T-cells during PDAC progression. In detail, we have characterized the functional proprieties of the different subsets of IL-22-producing CD4+ and CD8+ Tcc (T-cell clones) generated from lymphocytes that infiltrate PDAC tissue, and we analysed their relationship with the TNM staging system and patient survival.

**MATERIALS AND METHODS**

**Patients**

Tumours and corresponding adjacent tissues were obtained from 30 PDAC patients (14 males and 16 females), who were classified according to the TNM classification for pancreatic tumours [30]. The mean age of the PDAC patients was 66 years (range 36–92 years). The clinical characteristics of patients are summarized in Table 1. All patients underwent surgical resection of the primary lesion, but did not receive chemotherapy. Patients with evidence of serious illness, immunosuppression, or autoimmune or infectious diseases were excluded. The study was approved by the local Ethical Committees (Azienda Ospedaliera Universitaria Careggi) and informed consent was obtained from all patients.

**Generation of Tcc from TILs of the neoplastic pancreatic tissue**

T-cell cultures were performed in RPMI 1640 culture medium (SERO-Med) supplemented with 10% (v/v) HyClone™ FBS (Gibco Laboratories) and recombinant human IL-2 (EuroCetus). Surgical specimens of PDAC tissue were cultured for 7 days in RPMI 1640 medium supplemented with IL-2 (50 units/ml), in order to expand in vivo-activated TILs; in detail, tissue pieces from each patient were obtained from two different sites, namely tumour and surrounding healthy mucosa. Each specimen was then disrupted, and single T-cell blasts were cloned under limiting dilution, as described previously [31]. Briefly, single T-cell blasts were seeded in microwells (0.3 cell/well) in the presence of 2 × 10^5 irradiated (9000 rad) PBMCs (peripheral blood mononuclear cells), PHA (phytohaemagglutinin) (0.5%) and IL-2 (50 units/ml). At weekly intervals, 2 × 10^5 irradiated PBMCs and IL-2 were added to each micro-culture to maintain the expansion of growing clones. The Tcc were evaluated for their surface markers and functional proprieties, namely cytokine profile, B-cell helper activity and cell cytotoxicity.

**Analysis of cell-surface markers and evaluation of the cytokine profile of isolated Tcc**

Fluorochrome-conjugated anti-CD3, -CD4, -CD8 and isotype-matched control mAbs (monoclonal antibodies) were purchased from BD Biosciences. We analysed surface marker (CD3, CD4 and CD8) expression in blasts of single Tcc by flow cytometry, as described previously [31]. To evaluate the amount of secreted cytokines, T-cell blasts of single Tcc were resuspended at a concentration of 10^6 cells/ml of medium and cultured for 36 h in the presence of PMA (10 ng/ml) plus 5 S.D. above the mean levels of control IFN-γ, IL-4, IL-17 and IL-22 content using commercial ELISA kits (Bio-Source International). Supernatants presenting cytokine levels that were 5 S.D. above the mean levels of control supernatants derived from irradiated APCs (antigen-presenting cells) alone were regarded as positive. On the basis of the evaluation of the cytokine profile and the CD4/CD8 expression, we divided the clones into the following groups: Th22/Tc22 (only IL-22), Th22Th1/Tc22Th1 (IL-22+IFN-γ), Th22Th2/Tc22Th2 (IL22+IL-4), and Th22Th17/Tc22Th17 (IL-22+IL-17).

**B-cell helper activity**

B-cells were prepared using the B-cell isolation kit II (Miltenyi Biotec). A total of 2 × 10^5 B-cells were co-cultured with 10^5...
IFN-γ-producing Th22 cells negatively correlate with survival of PDAC patients

Table 1  Clinical parameters of patients with pancreatic cancer and Tcc isolated from cancer tissue

| Code | Age | Sex | TNM       | Tumour size (cm) | Metastasis | Overall Survival (months) | Tcc obtained | IL-22-producing Tcc (%) |
|------|-----|-----|-----------|------------------|------------|--------------------------|--------------|------------------------|
| 01.PDAP | 50  | Male | pT1, N1, Mx | >3               | –          | 11                       | 84           | 12 (14)                |
| 02.PDAP | 73  | Male | pT2, N1, Mx | >3               | –          | 13                       | 26           | 4 (15)                 |
| 03.PDAP | 56  | Male | pT3, N0, Mx | >3               | ++         | 8                        | 6            | 4 (67)                 |
| 04.PDAP | 36  | Male | pT4, N1, M1 | <3               | ++         | 7                        | 16           | 10 (63)                |
| 05.PDAP | 74  | Female | pT3, N1, Mx | >3               | ++         | 9                        | 91           | 55 (60)                |
| 06.PDAP | 61  | Female | pT4, N1, Mx | >3               | ++         | 8                        | 20           | 10 (50)                |
| 07.PDAP | 63  | Male | pT1, N1, Mx | >3               | –          | 12                       | 37           | 8 (22)                 |
| 08.PDAP | 74  | Female | pT4, N0, Mx | >3               | ++         | 8                        | 74           | 44 (59)                |
| 09.PDAP | 54  | Female | pT2, N0, Mx | >3               | –          | 14                       | 5            | 1 (20)                 |
| 10.PDAP | 92  | Male | pT3, N1, Mx | <3               | ++         | 9                        | 3            | 2 (67)                 |
| 11.PDAP | 57  | Male | pT2, N1, M1 | <3               | +          | 10                       | 22           | 8 (36)                 |
| 12.PDAP | 51  | Female | pT1, N1, Mx | >3               | –          | 11                       | 13           | 2 (15)                 |
| 13.PDAP | 72  | Female | pT4, N1, Mx | <3               | ++         | 8                        | 22           | 15 (68)                |
| 14.PDAP | 80  | Female | pT2, N1, M1 | <3               | –          | 12                       | 58           | 11 (19)                |
| 15.PDAP | 58  | Male | pT1, N0, Mx | <3               | +          | 13                       | 28           | 9 (32)                 |
| 16.PDAP | 55  | Female | pT1, N0, Mx | <3               | –          | 13                       | 11           | 2 (18)                 |
| 17.PDAP | 70  | Female | pT2, N1, Mx | >3               | +          | 11                       | 32           | 8 (25)                 |
| 18.PDAP | 62  | Female | pT3, N0, Mx | >3               | ++         | 8                        | 24           | 14 (58)                |
| 19.PDAP | 42  | Female | pT4, N1, M1 | >3               | ++         | 9                        | 10           | 6 (60)                 |
| 20.PDAP | 58  | Male | pT1, N0, Mx | >3               | –          | 11                       | 52           | 13 (25)                |
| 21.PDAP | 74  | Male | pT4, N1, Mx | >3               | ++         | 8                        | 31           | 25 (81)                |
| 22.PDAP | 79  | Female | pT4, N1, Mx | <3               | +          | 10                       | 28           | 14 (50)                |
| 23.PDAP | 83  | Male | pT4, N0, Mx | >3               | ++         | 8                        | 22           | 15 (68)                |
| 24.PDAP | 62  | Male | pT1, N0, Mx | >3               | –          | 12                       | 12           | 1 (8)                  |
| 25.PDAP | 85  | Female | pT1, N0, Mx | <3               | +          | 13                       | 8            | 3 (38)                 |
| 26.PDAP | 76  | Male | pT2, N1, M1 | <3               | +          | 12                       | 18           | 8 (44)                 |
| 27.PDAP | 71  | Male | pT1, N1, Mx | <3               | +          | 11                       | 7            | 2 (29)                 |
| 28.PDAP | 63  | Female | pT3, N1, Mx | >3               | ++         | 8                        | 11           | 7 (64)                 |
| 29.PDAP | 66  | Female | pT2, N1, M1 | <3               | –          | 14                       | 32           | 8 (25)                 |
| 30.PDAP | 72  | Female | pT4, N1, Mx | <3               | +          | 8                        | 4            | 2 (50)                 |
| All PDAC patients | 66 | 14 male/16 female | Pancreatic ductal adenocarcinoma | 10.3 | 807 | 323 (40) |

blasts of the different Th22/Tc22 Tcc subsets and stimulated with 100 ng/ml anti-CD3 mAb. On day 7, supernatants from each cell culture were collected and evaluated by ELISA for IgM, IgG, IgA and IgE content.

**Flow cytometric detection of granzyme A and evaluation of cell cytotoxicity**

Granzyme A expression by Tcc was assessed according to the manufacturer’s instructions (BD Biosciences). The different subpopulations of IL-22-producing Tcc were tested for their ability to kill P815 target cells upon anti-CD3 mAb activation (5 μg/ml) by evaluating the percentage of annexin V-binding cells using flow cytometry. The evaluation of apoptosis in Tcc and in L3.6pl tumour cells was performed using the Annexin V kit (BD Biosciences) following the manufacturer’s instructions. Cells were then analysed on a FACS Canto cytofluorimeter (BD Biosciences) using FACSDiva software.

**Tumour cell cultures and in vitro cytotoxicity assay**

Human PDAC L3.6pl cells (cell line kindly provided by Professor Paola Nisticò, Regina Elena National Cancer Institute, Rome, Italy) were cultured in DMEM (Dulbecco’s modified Eagle’s medium) (Lonza) supplemented with 10% (v/v) FBS (Lonza), L-glutamine (GE Healthcare) and 50 μg/ml gentamicin (Genta-lyn 40 mg/ml, Essex Italia) at 37°C in a 5% CO2 atmosphere. For the cytotoxicity assay, cells were seeded in 96-well plates at a density of 2×10^4 cells per well, incubated for 4 h and then starved overnight at 37°C. Cells were treated with 100 ng/ml IL-22 or IFNγ, or both, and incubated for 72 h; cell viability was then determined using the MTT assay (Sigma). Briefly, 20 μL/well of 5 mg/ml MTT solution in PBS was added and incubated for 4 h.
at 37 °C. Medium was removed and 100 μl of DMSO was added to each well. The formazan salts were quantified by reading the absorbance at a test wavelength of 570 nm.

**Immunohistochemical analysis**

The surgical specimens of PDAC tissue were fixed in 4% paraformaldehyde overnight at 4 °C, paraffin-embedded and cut using a rotary microtome (MR2, Boeckeler Instruments). For immunohistochemical staining, 5-μm sections of the blocks were incubated overnight with rabbit anti-human PD-1 (programmed cell death 1) mAb (clone EPR4877, 1:500 dilution; Abcam) or mouse anti-human FoxP3 (forkhead box P3) mAb antibody (clone 22510, 5 μg/ml, 1:200 dilution; Abcam); mouse anti-human CD4 mAb (neat, clone 4B12; Nichirei); mouse anti-human CD8 mAb (1:20 dilution, Dako Japan) or mouse anti-human CD163 antibody (1:100 dilution, Leica Biosystems). Following antibody incubation, samples were incubated at room temperature for 1 h with anti-rabbit or anti-mouse immunoglobulins conjugated to a horseradish peroxidase-labelled dansyl polymer (Simple Staining Kit; Nichirei). After a benzidine reaction, sections were lightly counterstained with haematoxylin.

For analysing the IL-22+ T-cells, sections were boiled for 10 min in sodium citrate buffer (10 mM, pH 6.0; Bio-Optica) for antigen retrieval, and incubated in 2 mg/ml glycine (Applichem) for 10 min, to quench autofluorescence of the elastic fibres. Non-specific binding was blocked by exposure to 1.5% BSA in PBS for 20 min at room temperature. Sections were immunolabelled overnight at 4 °C with mouse anti-CD3 mAb (ready to use; GeneTex) and goat polyclonal anti-IL-22 mAb (1:50 dilution; DAKO, Japan). Immunoreactions were visualized by incubation with specific anti-mouse and anti-goat Alexa Fluor® 488- or 568-conjugated IgG (1:300 dilution; Molecular Probes) for 2 h at room temperature. Negative controls were carried out by replacing the primary antibodies with non-immune serum. Digital images were obtained using an epifluorescence Leica Microsystems microscope equipped with a ×63 oil-immersion objective.

**Staining of peripheral Th22 cells**

PBMCs were isolated by density gradient centrifugation from heparinized venous blood of PDAC patients or healthy subjects. PBMC samples were characterized for their expression of IL-22, IL-17 and IFN-γ using intracellular cytokine staining, as described previously [23]. Briefly, fresh or thawed PBMCs were cultured in IMDM (Iscove’s modified Dulbecco’s medium) (BioWhittaker) supplemented with 10% FBS (Invitrogen) and stimulated for 5 h with PMA (50 ng/ml) and ionomycin (500 ng/ml) in the presence of BFA (brefeldin A) (10 μg/ml) (all from Sigma–Aldrich). Cells were first stained for the surface antigens CD4 (BD Biosciences), then fixed with 4% (w/v) paraformaldehyde and permeabilized with 0.5% saponin, followed by intracellular staining with anti-IL-22, anti-IL-17 and anti-IFN-γ mAbs (BD Biosciences).

**Statistical analysis**

Results are expressed as the median (range) or the mean (± S.D.). Comparisons between the two groups were assessed using Student’s t test. Correlations between the parameters were assessed using Pearson’s correlation analysis. SPSS statistical software (version 13.0) was used for all statistical analyses.

**RESULTS**

**Isolation of IL-22-producing T-cells from PDAC tissue**

To evaluate the intra-tumoral subsets of IL-22-producing (IL-22⁺) T-cells in PDAC patients, we expanded and cloned in vivo activated TILs isolated from two different sites, namely tumour and surrounding healthy pancreas. We isolated Tcc from each patient, and overall we obtained 807 Tcc; of these Tcc, 507 were isolated from the cancer, which was almost double the number of the Tcc isolated from the healthy pancreas (300) (Table 1). Evaluating the surface markers of Tcc, we noticed that 710 (out of 807) (88%) were positive for CD4 and the remaining 97 were positive for CD8 (12%). After mitogen stimulation, we assessed the levels of IL-22 secreted by single Tcc. We observed that 323 Tcc (40%) were able to produce IL-22 and, more precisely, 290 CD4⁺ and 33 CD8⁺ (Figure 1A). Of particular interest, the number of Th22 cells increased at the cancer site; we isolated 215 (74%) Th22 Tcc from the tumour and only 75 (26%) from the healthy mucosa. In addition, we registered similar data on the CD8⁺ population, isolating 25 out of 33 (76%) from the neoplastic tissue and only 8 (24%) from the surrounding healthy pancreatic tissue. Subsequently, we evaluated the IL-22 levels secreted by the Tcc, and we found that the IL-22-producing Tcc (both CD4⁺ and CD8⁺) isolated from the tumour tissue significantly (P < 0.0001) produced higher levels of IL-22 compared with the Tcc generated from the healthy pancreas (Figure 1B).

**Characterization of the cytokine profile of IL-22-producing Tcc**

As different T-cell subsets are able to produce IL-22, we also evaluated which of the 323 IL-22-producing Tcc also produced other cytokines. We observed that 61 (21%) out of 290 CD4⁺ Tcc only secreted IL-22 (pure Th22), whereas 12 (4%) co-secreted IL-4 (Th22/Th2), nine (3%) co-secreted IL-17 (Th22/Th17) and 44% (128/290) of the IL-22-producing Tcc were able to co-secrete IFN-γ (Th22/Th1). The remaining 80 (28%) CD4⁺ Tcc co-produced IFN-γ and IL-17 (Th22/Th1/Th17) (Figure 2A). Out of the 33 IL-22⁺ CD8⁺ Tcc, we found that 19 (58%) Tcc co-produced IFN-γ (Tc22/Tc1/Th1) and five (15%) also produced IL-4 (Tc22/Tc2). The final five CD8⁺ Tcc (16%) were only able to secrete IL-22 (Tc22) (Figure 2A).

**The IL-22-producing Tcc subsets exhibit different functional properties**

To define the functional properties of IL-22-producing Tcc, we then evaluated their ability to assist antibody production by B-cells and to display cytotoxic activity, which we then compared between the different IL-22⁺ Tcc. Both Th22/Th2 and...
IFN-γ-producing Th22 cells negatively correlate with survival of PDAC patients

Figure 1 Repertoire and IL-22 production of Tcc obtained from PDAC patients
(A) Total numbers of IL-22+ Tcc isolated from tumour tissue and the ratio of CD4+ CD8+ populations. The number of both CD4+ and CD8+ IL-22+ Tcc is higher in the cancer site. (B) Evaluation and comparison of the amount of IL-22 secreted, after mitogen stimulation, by the Tcc isolated from tumour tissue or surrounding healthy mucosa. The quantity of IL-22 produced by the Tcc (both CD4+ and CD8+) of tumour tissue is significantly (P < 0.0001) higher than that of Th22 cells isolated from healthy mucosa.

Figure 2 Cytokine profile and functional profile of intra-tumoral Th22 isolated from PDAC patients
(A) Distribution of Th22 subsets. The major representative Tcc subtype is the Th22 with Th1 profile, for both the CD4+ population (white column) and the CD8+ population (black column). The percentage of Tcc producing only IL-22 (by our definition, pure Th22) is 21 of CD4+ Th22 and 16 of CD8+ Tc22. (B) To assess the B-cell helper activity, we used autologous B-cells co-cultured with 10^5 blasts of the different Th22/Tc22 Tcc subsets, stimulated with anti-CD3 antibody. The supernatant content of different Ig subclasses was evaluated by commercial ELISA. (C) The granzyme A expression and the percentage of annexin V-binding cells (D) were assessed according to the manufacturer's instructions (BD Biosciences) and analysed on a FACSCanto cytofluorimeter (BD Biosciences) using FACSDiva software.
IL-22 reduced IFN-γ-induced apoptosis in pancreatic cells

As the majority of TILs produce IL-22 in combination with IFN-γ, we evaluated the effect of IL-22 alone in the presence of IFN-γ on the human pancreatic tumour cell line L3.6pl, which is a highly metastatic tumour cell line [32], the cells of which express IL-22 receptor on their membrane (Figure 3A). IL-22 alone increases the cell viability of L3.6pl cells (Figure 3B); as expected, IFN-γ treatment reduced cell viability (Figure 3B) and induced strong apoptosis (Figure 3C) of L3.6pl cells. Interestingly, these cytotoxic effects of IFN-γ were significantly reduced by the presence of IL-22 (Figures 3B and 3C).

Immunohistochemical evaluation of intra-tumoral IL-22+ T-cells

To verify whether the results obtained by the ex vivo model reflected a real situation, the presence of CD3+IL-22+ cells infiltrating PDAC tissues was evaluated using immunohistochemistry. Among the infiltrating CD3+ T-cells (Figure 4A), CD4+ T-cells were predominant compared with the CD8+ T-cells (results not shown). Figures 4(B) and 4(C) only show representative images of the T- (CD4+/CD8+) cell infiltration. FoxP3+ cells (Figure 4E), as well as PD-1+ cells (Figure 4F), were more frequently observed, suggesting that regulatory or activated CD4+ T-cells had infiltrated the PDAC tissues. Finally, we also documented that the number of CD3+ T-cells co-expressing IL-22 (Figure 4I) was higher in the neoplastic tissue. Table 2 shows the number of inflammatory cells which we assessed per high power field. Comparing the PDAC tissue with the surrounding healthy mucosa, we noted an increased number of CD4+, FoxP3+, PD-1+ and, especially, IL-22+ T-cells in the tumour tissue. Finally, we also documented that the number of IL-22-producing Tcc, isolated in a single patient, significantly correlated (P = 0.0076) with the number of tumour-infiltrating IL-22+ cells, thus creating an important link between the in vitro and in vivo data.

Th22 cells increase in the peripheral blood of PDAC patients

Finally, the frequency of Th22 cells was assessed in the peripheral blood of PDAC patients and 30 healthy subjects by flow cytometry. After gating CD4+ cells, we identified three different groups of IL-22-producing cells, namely one group producing IL-22 alone (termed Th22 cells), one co-producing IFN-γ and the last co-producing IL-17. The percentage of Th22 cells in the peripheral blood of PDAC patients was significantly higher than in age-matched healthy donors (Figure 5A). The expansion of Th22 cells was accompanied by the increase of IL-22/IFN-γ co-producing (Figure 5B) and IL-22/IL-17 co-producing (Figure 5C) CD4+ T-cells. However, the Th22 cell subset was the highest IL-22-producing group in the peripheral blood.

Clinical relevance of Th22 cells in PDAC patients

The statistical analysis showed that IL-22-producing Tcc positively correlated with TNM staging (Figure 6A) and metastases...
IFN-γ-producing Th22 cells negatively correlate with survival of PDAC patients

**Figure 4** Immunohistochemical analysis of PDAC tissues
Surgically resected PDAC tissues were immunohistochemically stained. CD3 (A): lymphoid aggregation around PDAC was mainly composed of CD3⁺ T-cells. CD4 (B): the majority of lymphoid aggregation was CD4⁺ T-cells. CD8 (C): the number of CD8⁺ T-cells was small compared with that of CD4⁺ T-cells shown in (B). Most T-cells were IL-22-positive (D), some were FoxP3-positive (E) (nuclear expression) and some were PD-1-positive (F). Magnification ×10 high power field. In the lower panels are digital images, obtained using an epifluorescence Zeiss Axioskop microscope equipped with a ×63 oil-immersion objective, of CD3⁺ T-cells (G), IL-22⁺ cells (H) and CD3⁺ IL-22⁺ T-cells (I). The images are from tissue of different patients and are representative images of high/low-expressing samples for each marker.

(Figure 6B), but were not related to the sex or tumour size (results not shown). Taken together, these results suggest that IL-22 expression by T-cells is closely associated with PDAC progression and with the patient outcome. To test this hypothesis, we evaluated whether the number of Th22 Tcc negatively correlated with the survival of PDAC patients. The patients were divided into two groups on the basis of the percentage of intra-tumoral IL-22-producing Tcc, either (i) <50% or (ii) ≥50% (Table 1). Kaplan–Meier analysis revealed that the patients of group (i) showed a better survival compared with group (ii) (P < 0.0001), suggesting a negative correlation between the percentage of IL-22-secreting Tcc and a better outcome of the disease (Figure 6C). In other words, elevated expression of intra-tumoral Th22 correlates with PDAC progression and is a predictor of poor patient survival.

**DISCUSSION**

IL-22 is a member of the IL-10 family of cytokines produced by T-cells and innate lymphoid cells [33]. The distribution of the two IL-22 receptors, IL-22R1 and IL-10R2, indicates that the most important target cells of IL-22 reside in the skin, digestive system (pancreas and liver), lungs, and kidney. In general, the IL-22 signalling pathway orchestrates mucosal immune responses and tissue regeneration through pleiotropic effects, including pro-survival signalling, cell migration, dysplasia and angiogenesis [34]. Although these functions can prevent the initial establishment of tumours, they can also be exploited by aggressive cancers to enhance tumour growth and metastasis. In fact, as well as being implicated in the pathogenesis of many autoimmune and
Table 2  Inflammatory features of PDAC tissue and surrounding healthy pancreas

The number of each inflammatory cells was assessed per high power field.

| Patient | Degree of inflammation | CD4 tumour/healthy mucosa | FoxP3 tumour/healthy mucosa | PD-1 tumour/healthy mucosa | IL-22 tumour/healthy mucosa |
|---------|------------------------|---------------------------|-----------------------------|----------------------------|----------------------------|
| 01.PDAp | Mild                   | >100/100                  | <10/10                      | <5/5                       | 38/27                      |
| 02.PDAp | Moderate               | 54/62                     | 58/22                       | 14/6                       | 45/31                      |
| 03.PDAp | Severe                 | 83/80                     | <10/10                      | 41/27                      | 62/48                      |
| 04.PDAp | Severe                 | >100/100                  | 24/10                       | 10/5                       | 73/49                      |
| 05.PDAp | Severe                 | 99/62                     | 32                          | 55/33                      | 77/59                      |
| 06.PDAp | Severe                 | 88/72                     | <10/10                      | <5/5                       | 65/51                      |
| 07.PDAp | Mild                   | >100/100                  | 37/20                       | <5/5                       | 18/8                       |
| 08.PDAp | Severe                 | 98/82                     | 25/15                       | 44/25                      | 63/48                      |
| 09.PDAp | Mild                   | >100/100                  | 15/10                       | 21/8                       | 72/54                      |
| 10.PDAp | Severe                 | 80/63                     | <10/10                      | 12/5                       | 61/53                      |
| 11.PDAp | Moderate               | >100/100                  | 22/10                       | 8/5                        | 61/49                      |
| 12.PDAp | Mild                   | 71/82                     | 13/10                       | 12/5                       | 38/29                      |
| 13.PDAp | Severe                 | >100/82                   | 22/15                       | 15/6                       | 70/56                      |
| 14.PDAp | Mild                   | 52/72                     | 48/34                       | <5/5                       | 55/46                      |
| 15.PDAp | Moderate               | >100/100                  | 28/17                       | 19/8                       | 47/38                      |
| 16.PDAp | Mild                   | 63/75                     | 11/10                       | 22/15                      | 22/15                      |
| 17.PDAp | Moderate               | >100/100                  | 32/20                       | 38/24                      | 45/36                      |
| 18.PDAp | Severe                 | 88/63                     | <10/10                      | <5/5                       | 65/54                      |
| 19.PDAp | Severe                 | 99/74                     | 18/11                       | 16/6                       | 79/57                      |
| 20.PDAp | Mild                   | >100/100                  | 35/21                       | 13/5                       | 68/51                      |
| 21.PDAp | Severe                 | >100/100                  | <10/10                      | 25/16                      | 72/49                      |
| 22.PDAp | Moderate               | >100/100                  | 28/21                       | 14/8                       | 76/51                      |
| 23.PDAp | Severe                 | 88/100                    | 22/12                       | 15/7                       | 67/53                      |
| 24.PDAp | Mild                   | 72/85                     | 12/10                       | <5/5                       | 54/42                      |
| 25.PDAp | Moderate               | >100/100                  | <10/10                      | 31/20                      | 19/8                       |
| 26.PDAp | Moderate               | 84/100                    | 18/10                       | 28/16                      | 23/15                      |
| 27.PDAp | Moderate               | >100/100                  | 27/18                       | 12/7                       | 75/52                      |
| 28.PDAp | Severe                 | >100/100                  | <10/10                      | <5/5                       | 78/49                      |
| 29.PDAp | Mild                   | >100/100                  | <10/10                      | 18/6                       | 49/31                      |
| 30.PDAp | Moderate               | 68/78                     | 14/10                       | 23/10                      | 71/59                      |

Figure 5  IL-22-producing cells in the peripheral blood of PDAC

Ex vivo FACS analysis of cytokine production from CD4+ T-cells in healthy subjects (HS) and in PDAC patients stimulated for 5 h with PMA and ionomycin in the presence of BFA. Results are the percentages of IL-22-producing CD4+ cells in the peripheral blood. *P < 0.001.
IL-22 tissue significantly produced higher IL-22 levels compared with related with the number of tumour-infiltrating IL-22 note, that the number of IL-22-producing Tcc significantly cor-
tissues compared with the surrounding healthy pancreas and, of isolates from PDAC patients was significantly elevated in PDAC stressed that the number of IL-22-producing CD4+ cells. We observed that some CD4+ Tcc only produced IL-22, but the majority of them co-produced IFN-γ alone or with IL-17, and similarly only five out of the 33 CD8+ Tcc, secreted IL-
22 alone, whereas many co-produced IFN-γ or both IFN-γ and IL-17. In conclusion, we have shown, for the first time, that in PDAC patients, the major intra-tumoral source of IL-22 is the T-cell subset with a Th1 profile.

Notably, as further confirmation of these ex vivo data, we also documented a similar trend in vivo; in detail, we showed that expansion of Th22 cells in the peripheral blood of PDAC patients was accompanied by an increase in IL-22/IFN-γ-co-producing and IL-22/IL-17-co-producing CD4+ T-cells.

As most of the IFN-γ-producing Tcc are able to exert perforin-
mediated cytotoxicity, we assessed the cytolytic potential of IL-
22+ Tcc and, as expected, only the Th22/Th1 Tcc showed a satisfactory expression of granzyme A, whereas the remaining different IL-22-producing Tcc subsets exhibited low levels of granzyme A. In addition, we registered analogous data about the ability to induce apoptosis. In all IL-22+ Tcc, only those co-
producing IFN-γ (Th22/Th1) displayed a significant percentage of annexin V-binding cells.

Indeed, as we have shown that PDAC cells express IL-22R, they are responsible for the anti-apoptotic effect of IL-22. We have shown that IFN-γ induced the apoptosis of PDAC cells and this apoptosis was antagonized by the addition of IL-22.

Taken together, these data support the hypothesis that IL-22 favours PDAC progression by inhibiting IFN-γ-induced apoptosis. The IL-22 production by intra-tumoral Th1/Th22 cells during PDAC progression may therefore neutralize the anti-tumour effect of Th1-polarized T-cells, protecting the cancer cells by the pro-apoptotic effect of IFN-γ [38].

Finally, to complete the functional characterization of intra-tumoral IL-22+ Tcc, we evaluated their ability to assist antibody production by B-cells. In agreement with previous studies [8], all of the different Th22 subsets of Tcc were unable to induce assistance for the production of IgE, but had

---

**Figure 6** Correlation between clinical parameters of patients and number of Th22 Tcc

Correlation between the percentages of Th22 cells with TNM stage (A) and presence of metastases (B). The increased number of IL-22+ TILs positively and significantly correlates with TNM PDAC staging and number of metastases: --, no metastases; +, metastases in one site; ++, multisite metastases. (C) To correlate the survival of PDAC patients with the number of Th22 Tcc, we divided the patients into two groups: (i) patients with Th22 Tcc ($\geq$50%), and (ii) the patients with Th22 Tcc ($<50$%). Correlating the two groups by the Kaplan–Meier curve, we observed that group (ii) showed significantly ($P < 0.0001$) better survival compared with group (i).
a similar ability to induce IgA. In addition, both Th22/Th2 and Th22/Th1 Tcc induced IgM production, whereas only the Th22 with a Th1 profile displayed an ability to induce IgG. In other words, IL-22 does not seem to affect the isotype switch of antibodies.

In summary, our results highlight the well-established dual role of the anti-tumour immune response in PDAC patients. Indeed, Th1 lymphocytes usually play an effector role against tumour cells by assaulting them and then blocking tumour growth [31,39,40]. Instead, in this context, the same Th1 cells, which produce IL-22, could promote tumour progression, as demonstrated recently in the pathogenesis of arthritis [41]. It is well known that the pro-survival and proliferative effects of IL-22 are utilized by many cancers; in particular, lung and liver cancers appear to be particularly sensitive to these effects [36,42,43]. In addition, IL-22 can promote carcinogenesis by favouring angiogenesis [44,45] or enhancing immune evasion by tumours [45]. PDAC cells themselves secrete VEGF (vascular endothelial growth factor) and TGF-β (transforming growth factor β) and IL-10 in response to IL-22 stimulation [45].

Finally, most importantly, our findings also shed light on the clinical relevance of Th22 cells in PDAC. We found that an increased frequency of Th22 cells correlated with TNM staging and with an unfavourable outcome of the disease, thus the number of IL-22-producing Tcc negatively correlated with PDAC patient survival.

Pancreatic cancer has a dismal 5-year survival rate of <5%, partly because most patients are diagnosed when the disease is already at an advanced stage, and partly because only 20% of patients have local resectable tumours [46,47]. Increased responsiveness to IL-22 may be the tipping point which separates resectable tumours from incurable and metastasized cancers (often already present at diagnosis). One study showed that the expression of both IL-22 and IL-22R1 was elevated in sections of PDAC tissue and predicted poorer patient survival [29]. However, a different group found that IL-22R1 was more poorly expressed in patients with PDAC compared with normal controls [48]. Primary cells and metastases of oral squamous cell carcinomas showed intense staining for IL-22Rα1 [49]. Nonetheless, a chromosomal loss of the region IL-22Rα1 was also found in a cohort of Sudanese patients, but not in Norwegian patients of the same study [50], mirroring the discrepancy between the results in immunohistochemical observation and array comprehensive genomic hybridization for pancreatic cancer. These data reveal how differences in genotypes between ethnic groups may affect the significance of IL-22 in a given cancer. IL-22R1 may also be more affected specifically in buccal oral squamous cell carcinoma, which the majority of Sudanese patients had, but was absent from the Norwegian cohort.

In conclusion, our data demonstrate that all IL-22-producing T-cells are significantly increased in pancreatic cancer. Furthermore, these increases positively correlated with TNM staging of PDAC and poorer patient survival. These novel findings suggest that Th22 cells may participate in PDAC pathogenesis, that the monitoring of Th22 can be a good diagnostic parameter and, finally, that blockade of IL-22 signalling may represent a viable method for anti-PDAC therapies.

**CLINICAL PERSPECTIVES**

- The principal sources of IL-22 are Th22 cells, which secrete only IL-22 or other cytokines such as IL-17 or IFN-γ. Intra-tumoral IL-22 levels were elevated in PDAC (pancreatic ductal adenocarcinoma). However, the nature, role and clinical relevance of Th22 remain unknown.
- We have shown that in PDAC patients, cytotoxic IFN-γ+ Th22 cells are the major intra-tumoral source of IL-22, which induce apoptosis, and are antagonized by IL-22. The increased levels of Th22 positively correlated with TNM and poorer patient survival.
- Elucidation of how IL-22 regulates the pathogenesis of PDAC is important, and may help to identify a new target for developing innovative PDAC treatments.

**AUTHOR CONTRIBUTION**

Elena Niccolai, Amedeo Amedei and Francesco Novelli conceived and designed the study, and drafted the paper. Elena Niccolai, Simona Rolla, Francesca Castiglione, Federica Ricci, Marisa Bengaglio and Alessandro Pini acquired experimental data. Antonio Taddei, Paolo Bechi, Lapo Bencini, Maria Novella Ringressi, Andrea Coratti, Fabio Cianchi, Daniele Giordano and Maria Antonietta Satolli were involved in enrolment and obtaining clinical data of patients. Elena Niccolai, Mario Milco D’Elisio, Daniele Bani, Simona Rolla, Francesco Novelli and Amedeo Amedei analysed and interpreted data. Amedeo Amedei, Francesco Novelli and Domenico Prisco critically revised the paper.

**ACKNOWLEDGEMENTS**

We thank Radhika Srinivasan for a critical reading of the paper before submission.

**FUNDING**

This work was supported by the Italian Ministry of University and Research (PRIN 2009), Cassa di Risparmio Foundation, the Associazione Italiana Ricerca sul Cancro (grant number 15232 and 5 per mille grant number 12182), University of Turin-Progetti Ateneo 2014-Compagnia di San Paolo (PC-METAIMMUNOTHER), Cariplo Foundation, Fondazione Ricerca Molinette and Fondazione Ursula e Giorgio Cytron.

**REFERENCES**

1. Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. CA Cancer J. Clin. 61, 69–90 CrossRef PubMed
2. Hartwig, W., Werner, J., Jäger, D., Debus, J. and Büchler, M.W. (2013) Improvement of surgical results for pancreatic cancer. Lancet Oncol. 14, e476–e485 CrossRef PubMed
3. Kolodecik, T., Shugrue, C., Ashat, M. and Thrower, E.C. (2014) Risk factors for pancreatic cancer: underlying mechanisms and potential targets. Front. Physiol. 4, 415 CrossRef PubMed
4. Candido, J. and Hagemann, T. (2013) Cancer-related inflammation. J. Clin. Immunol. 33 Suppl., S79–S84 CrossRef PubMed
IFN-γ-producing Th22 cells negatively correlate with survival of PDAC patients

Lin, W.W. and Karin, M. (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117, 1175–1183 CrossRef PubMed

Witte, E., Witte, K., Warszawski, K., Sabat, R. and Wolk, K. (2010) Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev. 21, 365–389 CrossRef PubMed

Wu, JW., Li, J., Kodangattii, S.R., Luxenberg, D.P., Bennett, F., Martino, C., Collins, M., Dunussi-Joannopoulos, K., Gill, S.S., Woflmann, N.M. et al. (2008) IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22. J. Mol. Biol. 382, 1168–1183 CrossRef PubMed

Lečart, S., Morel, F., Noraz, N., Pene, J., Garcia, M., Boniface, K., Lecron, J.C. and Yssel, H. (2002) IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int. Immunol. 14, 1351–1356 CrossRef PubMed

Radaeva, S., Sun, R., Pan, H.N., Hong, F. and Gao, B. (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39, 1332–1342 CrossRef PubMed

Wolk, K., Witte, E., Wallace, E., Döcke, W.D., Kunz, S., Asadullah, K., Volk, H.D., Sterry, W. and Sabat, R. (2006) IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 36, 1309–1323 CrossRef PubMed

Nagalakshmi, M.L., Rascle, A., Zuwarski, S., Menon, S. and de Waal Malefyt, R.F. (2004) Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int. Immunopharmacol. 4, 679–681 CrossRef PubMed

Aggarwal, S., Xie, M.H., Maruoka, M., Foster, J. and Gurey, A.L. (2001) Acinar cells of the pancreas are a target of interleukin-22. J. Interferon Cytokine Res. 21, 1047–1053 CrossRef PubMed

Shioya, M., Andoh, A., Kinoki, S., Nishida, A. and Fujiyama, Y. (2008) Interleukin-22 receptor 1 expression in pancreas islets. Pancreas 36, 197–199 CrossRef PubMed

Sanos, S.L., Bui, V.L., Moreta, A., Oberle, K., Heners, C., Johner, C. and Diefenbach, A. (2009) RORγt and commensal microflora are required for the differentiation of mucosal interleukin-22-producing Nkp46+ cells. Nat. Immunol. 10, 83–91 CrossRef PubMed

Takatori, H., Kanno, Y., Watford, W.T., Tato, C.M., Weiss, G., Ivanov, I.I., Littman, D.R. and O’Shea, J.J. (2009) Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J. Exp. Med. 206, 35–41 CrossRef PubMed

Goto, M., Murakawa, M., Kadoshima-Yamaoka, K., Tanaka, Y., Nagahira, K., Fukuda, Y. and Nishimura, T. (2009) Murine NKT cells produce Th17 cytokine interleukin-22. Cell. Immunol. 254, 81–84 CrossRef PubMed

Nogales, K.E., Zaba, L.C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J.G., Benagiano, M., Bencini, L., Bernini, M., Farsi, M., Moretti, R. et al. (2009) Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma. Int. Immunol. 21, 125–132 CrossRef PubMed

Warshaw, A.L. and Fernandez-del Castillo, C. (1992) Pancreatic carcinoma. N. Engl. J. Med. 326, 455–465 CrossRef PubMed

Amedei, A., Nicolai, E., Della Bella, C., Cianchi, F., Trallori, G., Benagiano, M., Bencini, L., Bernini, M., Farsi, M., Moretti, R. et al. (2009) Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma. Cancer Immunol. Immunother. 58, 1819–1830 CrossRef PubMed

Brus, C.J., Harbison, M.T., Kuniyasu, H., Eue, I. and Fidler, I.J. (1999) In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1, 50–62 CrossRef PubMed

Trifirò, S. and Sipits, H. (2010) IL-22-producing CD4+ T cells: middle-men between the immune system and its environment. Eur. J. Immunol. 40, 2369–2371 CrossRef PubMed

Wolk, K., Kunz, S., Witte, E., Friedrich, M., Asadullah, K. and Sabat, R. (2004) IL-22 enhances the innate immune response of tissues. Immunity 21, 241–254 CrossRef PubMed

Lo, Y.H., Torii, K., Fujisawa, T., Maeda, A. and Morita, A. (2010) Serum IL-22 correlates with psoriatic severity and predicts serum IL-6 correlates with susceptibility to phototherapy. J. Dermatol. Sci. 58, 225–227 CrossRef PubMed

Jiang, R., Tan, Z., Deng, L., Chen, Y., Xia, Y., Gao, Y., Wang, X. and Sun, B. (2011) Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 54, 900–909 CrossRef PubMed
37 Gurney, A.L. (2004) IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. Int. Immunopharmacol. 4, 669–677 CrossRef PubMed

38 Regis, G., Conti, L., Boselli, D. and Novelli, F. (2006) IFNγ-R2 trafficking tunes IFNγ–STAT1 signaling in T lymphocytes. Trends Immunol. 27, 96–101 CrossRef PubMed

39 Sideras, K., Braat, H., Kwekkeboom, J., van Eijck, C.H., Peppelenbosch, M.P., Sleijfer, S. and Bruno, M. (2014) Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat. Rev. 40, 513–522 CrossRef PubMed

40 Amedei, A., Niccolai, E., Benagiano, M., Della Bella, C., Cianchi, F., Bechi, P., Taddei, A., Bencini, L., Farsi, M., Cappello, P et al. (2013) Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunol. Immunother. 62, 1249–1260 CrossRef PubMed

41 Justa, S., Zhou, X. and Sarkar, S. (2014) Endogenous IL 22 plays a dual role in arthritis: regulation of established arthritis via IFNγ responses. PLoS One 9, e93279 CrossRef PubMed

42 Zhang, W., Chen, Y., Wei, H., Sun, R., Zhang, J. and Tian, Z. (2008) Antia apoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin. Cancer Res. 14, 6432–6439 CrossRef PubMed

43 Ye, Z.J., Zhou, Q., Yin, W., Yuan, M.L., Yang, W.B., Xiang, F., Zhang, J.C., Xin, J.B., Xiong, X.Z. and Shi, H.Z. (2012) Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett. 326, 23–32 CrossRef PubMed

44 Curd, L.M., Favor, J.E. and Gregg, R.K. (2012) Pro-tumour activity of interleukin-22 in HPAFII human pancreatic cancer cells. Clin. Exp. Immunol. 168, 192–199 CrossRef PubMed

45 Eyerich, S., Eyerich, K., Pennino, D., Carbone, T., Nasorri, F., Pallotta, S., Cianfarani, F., Odorisco, T., Traidl-Hoffmann, C., Behrendt, H. et al. (2009) Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J. Clin. Invest. 119, 3573–3585 PubMed

46 Hidalgo, M. (2010) Pancreatic cancer. N. Engl. J. Med. 362, 1605–1617 CrossRef PubMed

47 Vincent, A., Herman, J., Schülíck, R., Hruban, R.H. and Goggins, M. (2011) Pancreatic cancer. Lancet 378, 607–620 CrossRef PubMed

48 Crgorac-Jurcevic, T., Chelala, C., Barry, S., Harada, T., Bhakta, V., Lattimore, S., Jurcevic, S., Bronner, M., Lemoine, N.R. and Brentnall, T.A. (2013) Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS One 8, e54830 CrossRef PubMed

49 Naher, L., Kiyoshima, T., Kobayashi, I., Wada, H., Nagata, K., Fujiwara, H., Okuma, Y.F., Ozeki, S., Nakamura, S. and Sakai, H. (2012) STAT3 signal transduction through interleukin-22 in oral squamous cell carcinoma. Int. J. Oncol. 41, 1577–1586 PubMed

50 Roman, E., Meza-Zepeda, L.A., Kresse, S.H., Myklebost, O., Vassstrand, E.N. and Ibrahim, S.O. (2008) Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization. Oncol. Rep. 20, 825–843 PubMed